| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Melanocyte protein PMEL, ME20-M, ME20M, Melanocyte protein Pmel 17, Melanocytes lineage-specific antigen GP100, Melanoma-associated ME20 antigen, P1, P100, Premelanosome protein, Silver locus protein homolog, M-alpha, 95 kDa melanocyte-specific secreted glycoprotein, P26, Secreted melanoma-associated ME20 antigen, ME20-S, ME20S, M-beta, PMEL, D12S53E, PMEL17, SILV |
| Entrez GeneID | 6490 |
| WB Predicted band size | 70.3kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This SILV antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 412-440 amino acids from the Central region of human SILV. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SILV(PMEL)抗体的3-4篇参考文献及其摘要内容的简要总结：
---
1. **文献名称**：*"The Silver locus product (Pmel17/gp100) regulates melanosome biogenesis*"
**作者**：Theos, A.C., et al.
**摘要**：该研究利用SILV抗体(针对PMEL/gp100蛋白)揭示了PMEL在黑素体成熟过程中的关键作用。通过免疫荧光和电镜技术，作者发现PMEL蛋白在黑素体膜上形成纤维结构，调控黑色素沉积和细胞器形态，为黑色素瘤标志物研究提供了基础。
2. **文献名称**：*"Distinct protein sorting and localization during melanosome biogenesis*"
**作者**：Raposo, G., et al.
**摘要**：本文通过SILV抗体进行免疫定位分析，证明PMEL蛋白在黑素体早期形成阶段特异性表达，并参与其结构组装。研究强调了SILV抗体在追踪黑素体生物发生和蛋白分选机制中的重要性。
3. **文献名称**：*"Gene expression profiling of human melanocyte differentiation using SILV antibodies*"
**作者**：Hoek, K.S., et al.
**摘要**：研究结合基因表达谱分析和SILV抗体免疫染色，揭示了PMEL在黑色素细胞分化中的动态表达模式，并验证其作为黑色素瘤诊断标志物的潜在价值，为肿瘤免疫治疗提供新视角。
4. **文献名称**：*"Structural and functional analysis of the PMEL17/silver locus*"
**作者**：Kwon, B.S., et al.
**摘要**：早期研究通过制备SILV多克隆抗体，鉴定了PMEL蛋白的抗原表位及其在黑素细胞中的表达模式，为后续黑素体功能研究和抗体开发奠定了基础。
---
这些文献涵盖了SILV抗体在蛋白功能、亚细胞定位、疾病标志物验证等方向的应用，反映了其在黑色素研究和肿瘤学中的重要性。
The SILV gene, also known as PMEL or gp100. encodes a melanocyte-specific glycoprotein critical for melanosome maturation and pigment production. Expressed predominantly in skin, retinal pigment epithelium, and melanoma cells, the SILV protein facilitates melanosome structural organization by forming amyloid fibrils that scaffold melanin deposition. Its role in melanogenesis and association with malignant transformation has made SILV a key focus in melanoma research.
SILV antibodies are widely used to study melanocyte biology, tumor progression, and metastatic behavior. In diagnostics, these antibodies help identify melanoma cells in histopathology (e.g., HMB-45 antibody targeting SILV's non-amyloid core) and distinguish melanocytic tumors from other malignancies. Therapeutically, SILV-derived peptides serve as targets for immunotherapy, including cancer vaccines and adoptive T-cell therapies, leveraging its immunogenic properties.
Though SILV is not a direct oncogene, its overexpression in aggressive melanomas correlates with poor prognosis. Current research explores SILV's interplay with autophagy, drug resistance, and its potential as a biomarker for treatment response. However, off-target effects in non-melanocytic tissues remain a challenge for SILV-targeted therapies.
×
